The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
News|Articles|December 31, 2006
Stop That Itch Cold in Its Tracks!
To relieve an itch, have patients ruban ice cube over the affected areainstead of scratching with their fingernails.
Advertisement
To relieve an itch, have patients rub an ice cube over the affected area instead of scratching with their fingernails. This helps break the vicious “itch, scratch, itch, scratch” cycle.
- Charles J. Nagy, MD
La Jolla, Calif
Advertisement
Related to this article
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
2
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
3
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5